AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9234049 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 9234049 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine
Number of subjects: 6
Study 8148031 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc phosphate cement (Phosphacap)
Number of subjects: 12
Study 8148031 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass-ionomer cement (Ketac-Cem Maxicap)
Number of subjects: 12
Study 3527692 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory information about the exam
Number of subjects: 79
Study 3527692 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in coping skills (deep breathing and positive self‐talk)
Number of subjects: 79
Study 3527692 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined sensory information and coping skills training
Number of subjects: 79
Study 3527692 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 79
Study 3527692 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 79
Study 29910052 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral artery disease (PAD) patients
Number of subjects: 4098
Study 29910052 — intervention group
Group type: EXPERIMENTAL
Intervention: First nonfatal ischemic event in PAD patients
Number of subjects: 4098
Study 26980847 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical masks
Number of subjects: 0
Study 26980847 — intervention group
Group type: EXPERIMENTAL
Intervention: Cloth masks
Number of subjects: 0
Study 26980847 — intervention group
Group type: COMPARATOR
Intervention: Adverse events
Number of subjects: 0
Study 26980847 — intervention group
Group type: COMPARATOR
Intervention: Aerosol-generating procedures
Number of subjects: 0
Study 26980847 — intervention group
Group type: COMPARATOR
Intervention: Contact with febrile respiratory illness patients
Number of subjects: 0
Study 26980847 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliance with medical or cloth masks (average use ≥70% of working time)
Number of subjects: 0
Study 24139558 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (2.5mg/kg every 12 hours for 48 hours intravenously)
Number of subjects: 50
Study 24139558 — intervention group
Group type: COMPARATOR
Intervention: Placebo (isotonic saline 1.25 ml/kg/doses intravenously every 12 hours for 48 hours)
Number of subjects: 50
Study 24139558 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 50
Study 22337227 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA-rich fish oil (1.1 g/d n-3 LCPUFA)
Number of subjects: 78
Study 22337227 — intervention group
Group type: COMPARATOR
Intervention: Control (no fish oil)
Number of subjects: 78
Study 20410410 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ungated MDCT
Number of subjects: 584
Study 18580613 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate antiretroviral therapy (ART)
Number of subjects: 63
Study 18580613 — intervention group
Group type: COMPARATOR
Intervention: Deferred antiretroviral therapy (ART)
Number of subjects: 63
Study 15955616 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg conjugated equine estrogen (CEE) + 2.5 mg medroxyprogesterone acetate (MPA)
Number of subjects: 30
Study 15955616 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg estradiol valerate
Number of subjects: 30
Study 15955616 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg tibolone
Number of subjects: 30
Study 12217947 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen (15 mg/day for the first 3 days, then 30 mg/day for 27 days)
Number of subjects: 39
Study 12217947 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen
Number of subjects: 39
Study 12217947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 10028213 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed-syndrome children
Number of subjects: 0
Study 10028213 — intervention group
Group type: COMPARATOR
Intervention: Overall tendencies
Number of subjects: 0
Study 8607000 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic CPAP therapy (Continuous Positive Airway Pressure)
Number of subjects: 0
Study 8607000 — intervention group
Group type: COMPARATOR
Intervention: Normocapnic OSA and overlap group
Number of subjects: 0
Study 8607000 — intervention group
Group type: COMPARATOR
Intervention: Chronic hypercapnic OSA
Number of subjects: 0
Study 2385125 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinfusion of autologous platelet-rich plasma
Number of subjects: 18
Study 2385125 — intervention group
Group type: COMPARATOR
Intervention: No reinfusion of platelet-rich plasma (control group)
Number of subjects: 18
Study 7386493 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid hormone
Number of subjects: 20
Study 7386493 — intervention group
Group type: COMPARATOR
Intervention: Placebo medication
Number of subjects: 20
Study 31704188 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral calcitriol at 0.25 μg, 3 times weekly with ACEI or ARB
Number of subjects: 60
Study 31704188 — intervention group
Group type: COMPARATOR
Intervention: ACEI or ARB (control group)
Number of subjects: 60
Study 30945478 — intervention group
Group type: EXPERIMENTAL
Intervention: High Concentration Oxygen Therapy (HCOT)
Number of subjects: 96
Study 30945478 — intervention group
Group type: COMPARATOR
Intervention: Titrated Oxygen Therapy (TOT)
Number of subjects: 96
Study 27020489 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 μg sublingual misoprostol with cervical laminaria
Number of subjects: 70
Study 27020489 — intervention group
Group type: COMPARATOR
Intervention: 400 μg sublingual misoprostol without laminaria
Number of subjects: 70
Study 25821725 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% imiquimod cream
Number of subjects: 40
Study 25821725 — intervention group
Group type: COMPARATOR
Intervention: 10% KOH solution
Number of subjects: 40
Study 23594463 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin V 1.6 million units thrice-daily for 10 days
Number of subjects: 210
Study 23594463 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin 1,000 mg thrice-daily for 10 days
Number of subjects: 210
Study 21386066 — intervention group
Group type: EXPERIMENTAL
Intervention: 60‐second video training (n=95)
Number of subjects: 336
Study 21386066 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐minute video training (n=99)
Number of subjects: 336
Study 21386066 — intervention group
Group type: EXPERIMENTAL
Intervention: 8‐minute video training, including manikin practice (n=91)
Number of subjects: 336
Study 21386066 — intervention group
Group type: EXPERIMENTAL
Intervention: All experimental groups
Number of subjects: 336
Study 21386066 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=51)
Number of subjects: 336
Study 19561521 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured isotonic strength training (ST) program, 24 sessions (3 per week for 8 weeks).
Number of subjects: 16
Study 19561521 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 16
Study 17666194 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan (an ARB)
Number of subjects: 0
Study 17666194 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with telmisartan and ramipril (an ACE inhibitor)
Number of subjects: 0
Study 14629234 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centred guidebook
Number of subjects: 240
Study 14629234 — intervention group
Group type: COMPARATOR
Intervention: Control group (no guidebook)
Number of subjects: 240
Study 11084548 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravaginal misoprostol (600 microg vaginally)
Number of subjects: 9
Study 9487348 — intervention group
Group type: EXPERIMENTAL
Intervention: Colistin (2 MU tds intravenously) alone
Number of subjects: 53
Study 9487348 — intervention group
Group type: EXPERIMENTAL
Intervention: Colistin (2 MU tds intravenously) with a second anti-pseudomonal antibiotic (dual therapy)
Number of subjects: 53
Study 9487348 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 53
Study 8368227 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate 30 mg
Number of subjects: 50
Study 8368227 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate 60 mg
Number of subjects: 50
Study 8368227 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate 90 mg
Number of subjects: 50
Study 8368227 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate (all doses)
Number of subjects: 50
Study 3521761 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate and cyclosporine (n = 22)
Number of subjects: 46
Study 3521761 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate alone (n = 24)
Number of subjects: 46
Study 31732742 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 18924
Study 31732742 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18924
Study 30693611 — intervention group
Group type: EXPERIMENTAL
Intervention: Project-based treatment (20 hours over 6 weeks)
Number of subjects: 21
Study 30693611 — intervention group
Group type: COMPARATOR
Intervention: Waitlist group (control)
Number of subjects: 21
Study 28800382 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole prophylaxis (200 mg of SMX/40 mg of TMP once daily)
Number of subjects: 136
Study 28800382 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimens of 30 mg kg-1 of SMX and 6 mg kg-1 of TMP for the 5-10 kg group and 25 mg kg-1 of SMX and 5 mg kg-1 of TMP for the 10-15 kg group
Number of subjects: 136
Study 25887433 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive cardiac rehabilitation program (12 weeks of physical exercise and psycho-educational intervention with five consultations)
Number of subjects: 210
Study 25887433 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 210
Study 23969513 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab combined with trastuzumab and docetaxel
Number of subjects: 37
Study 23969513 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Number of subjects: 37
Study 23969513 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab and docetaxel
Number of subjects: 37
Study 23969513 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab, trastuzumab, and docetaxel combination
Number of subjects: 37
Study 21855741 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance Counseling group (n=64)
Number of subjects: 130
Study 21855741 — intervention group
Group type: COMPARATOR
Intervention: Contact Control group (n=66)
Number of subjects: 130
Study 19891902 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical cytology plus HPV testing (revealed arm)
Number of subjects: 24510
Study 19891902 — intervention group
Group type: COMPARATOR
Intervention: Cervical cytology (concealed arm)
Number of subjects: 24510
Study 17805238 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate
Number of subjects: 90
Study 17805238 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer
Number of subjects: 90
Study 17805238 — intervention group
Group type: COMPARATOR
Intervention: Low-phosphorus diet alone
Number of subjects: 90
Study 15541448 — intervention group
Group type: EXPERIMENTAL
Intervention: bivalent HPV-16/18 L1 virus-like particle vaccine
Number of subjects: 1113
Study 15541448 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1113
Study 11922382 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive screening programme with regular visual assessments by orthoptists (testing visual acuity, ocular alignment, stereopsis, and non-cycloplegic photorefraction)
Number of subjects: 3689
Study 11922382 — intervention group
Group type: COMPARATOR
Intervention: Visual surveillance only (control group)
Number of subjects: 3689
Study 11922382 — intervention group
Group type: EXPERIMENTAL
Intervention: Photorefraction
Number of subjects: 3689
Study 11922382 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual acuity testing plus cover test
Number of subjects: 3689
Study 9734613 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem CD
Number of subjects: 21
Study 9734613 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine GITS
Number of subjects: 21
Study 8034784 — intervention group
Group type: EXPERIMENTAL
Intervention: SofScale calculus scaling gel
Number of subjects: 32
Study 8034784 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 2659679 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of heat‐killed Leishmania mexicana amazonensis promastigotes and viable BCG
Number of subjects: 217
Study 2659679 — intervention group
Group type: EXPERIMENTAL
Intervention: Meglumine antimoniate chemotherapy
Number of subjects: 217
Study 2659679 — intervention group
Group type: COMPARATOR
Intervention: BCG alone
Number of subjects: 217
Study 2659679 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined immunotherapy
Number of subjects: 217
Study 31711041 — intervention group
Group type: EXPERIMENTAL
Intervention: Mézières method postural therapy (60 minutes, 2-3 sessions per week for 24 weeks)
Number of subjects: 90
Study 31711041 — intervention group
Group type: EXPERIMENTAL
Intervention: Mézières method postural therapy
Number of subjects: 90
Study 29855308 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 weeks of aerobic exercise, 3 times a week, 20 minutes per session
Number of subjects: 65
Study 28263203 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic OHT at 3 minutes after standing
Number of subjects: 1176
Study 28263203 — intervention group
Group type: COMPARATOR
Intervention: Orthostatic hypotension (OH)
Number of subjects: 1176
Study 28263203 — intervention group
Group type: COMPARATOR
Intervention: Orthostatic hypertension (OHT)
Number of subjects: 1176
Study 25535985 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 25 mg weekly (group A, 159 patients)
Number of subjects: 524
Study 25535985 — intervention group
Group type: COMPARATOR
Intervention: Etanercept 25 mg bi-weekly (group B, 164 patients)
Number of subjects: 524
Study 25535985 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 25 mg weekly (group A)
Number of subjects: 524
Study 25535985 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept half-dose regimen
Number of subjects: 524
Study 23844093 — intervention group
Group type: EXPERIMENTAL
Intervention: 100%CAPS
Number of subjects: 4
Study 23844093 — intervention group
Group type: EXPERIMENTAL
Intervention: 75%CAPS
Number of subjects: 4
Study 23844093 — intervention group
Group type: COMPARATOR
Intervention: 75%Control
Number of subjects: 4
Study 23844093 — intervention group
Group type: COMPARATOR
Intervention: 100%Control
Number of subjects: 4
Study 21696359 — intervention group
Group type: EXPERIMENTAL
Intervention: Dark chocolate intake (mild: 1-2 bars/week, moderate: 3-4 bars/week, high: > 4 bars/week)
Number of subjects: 14310
Study 21696359 — intervention group
Group type: EXPERIMENTAL
Intervention: Dark chocolate intake
Number of subjects: 14310
Study 21696359 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dark chocolate intake
Number of subjects: 14310
Study 19835299 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-based navigation
Number of subjects: 25
Study 16882265 — intervention group
Group type: COMPARATOR
Intervention: Closure of both the visceral and parietal peritoneum (C-group, n = 70)
Number of subjects: 124
Study 16882265 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-closure of the peritoneum (NC-group, n = 54)
Number of subjects: 124
Study 14988134 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer prompts from the R2 ImageChecker 1000
Number of subjects: 50
Study 14988134 — intervention group
Group type: COMPARATOR
Intervention: No prompts (unprompted condition)
Number of subjects: 50
Study 11248713 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with heart failure
Number of subjects: 1382
Study 11248713 — intervention group
Group type: COMPARATOR
Intervention: Men with heart failure
Number of subjects: 1382
Study 9037216 — intervention group
Group type: EXPERIMENTAL
Intervention: White, Hispanic, and Asian students
Number of subjects: 83
Study 9037216 — intervention group
Group type: EXPERIMENTAL
Intervention: White and Hispanic students
Number of subjects: 83
Study 9037216 — intervention group
Group type: EXPERIMENTAL
Intervention: White and Asian students
Number of subjects: 83
Study 9037216 — intervention group
Group type: EXPERIMENTAL
Intervention: White student
Number of subjects: 83
Study 9037216 — intervention group
Group type: COMPARATOR
Intervention: Black student
Number of subjects: 83
Study 7633085 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of thermal drape during anaesthesia
Number of subjects: 0
Study 7633085 — intervention group
Group type: COMPARATOR
Intervention: No thermal drape during anaesthesia
Number of subjects: 0
Study 3388405 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% Hartmann's + 50% 5% Dextrose (HD)
Number of subjects: 29
Study 3388405 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% Hartmann's (H)
Number of subjects: 29
Study 3388405 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% Plasmalyte 148 (P)
Number of subjects: 29
Study 3388405 — intervention group
Group type: EXPERIMENTAL
Intervention: CPD stored blood
Number of subjects: 29
Study 3388405 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate buffer
Number of subjects: 29
Study 31135225 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic supplement (109 CFU/day) for 10 weeks
Number of subjects: 88
Study 31135225 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 30978268 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum (GG) three times per day
Number of subjects: 75
Study 30978268 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PG)
Number of subjects: 75
Study 30978268 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum (GG)
Number of subjects: 75
Study 28601003 — intervention group
Group type: COMPARATOR
Intervention: Usual care (RT1) - moderate intensity (50% 1‐repetition maximum), low volume
Number of subjects: 62
Study 28601003 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intensity (RT2) - higher intensity (75% 1‐RM) and higher volume
Number of subjects: 62
Study 28601003 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity but higher volume (RT3)
Number of subjects: 62
Study 28601003 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined aerobic training (AT) and resistance training (RT)
Number of subjects: 62
Study 26711822 — intervention group
Group type: EXPERIMENTAL
Intervention: MIS‐TLIF using a tubular retraction system
Number of subjects: 96
Study 26711822 — intervention group
Group type: COMPARATOR
Intervention: Traditional TLIF
Number of subjects: 96
Study 23339584 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT) - up to 12 sessions in addition to usual care
Number of subjects: 36
Study 23339584 — intervention group
Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 36
Study 16984012 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 9426 (0.6 mg x kg(‐1))
Number of subjects: 88
Study 16984012 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 9426 (0.9 mg x kg(‐1))
Number of subjects: 88
Study 16984012 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium (0.1 mg x kg(‐1))
Number of subjects: 88
Study 16984012 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 9426 (0.15 mg x kg(‐1))
Number of subjects: 88
Study 12580930 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox/GHRH test
Number of subjects: 35
Study 12580930 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH/arginine test
Number of subjects: 35
Study 12580930 — intervention group
Group type: COMPARATOR
Intervention: Insulin tolerance test (ITT)
Number of subjects: 35
Study 12580930 — intervention group
Group type: COMPARATOR
Intervention: Acipimox/GHRH test in controls
Number of subjects: 35
Study 12580930 — intervention group
Group type: COMPARATOR
Intervention: Correlation with ITT
Number of subjects: 35
Study 12580930 — intervention group
Group type: COMPARATOR
Intervention: Correlation with GHRH/arginine test
Number of subjects: 35
Study 10754734 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoventricular plasty with patch (group A)
Number of subjects: 33
Study 10754734 — intervention group
Group type: COMPARATOR
Intervention: Endoventricular plasty without patch (group B)
Number of subjects: 33
Study 10754734 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B) after surgery
Number of subjects: 33
Study 7739102 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam-famotidine suppository (0.5 mg.kg‐1 midazolam and 2 mg.kg‐1 famotidine)
Number of subjects: 45
Study 7739102 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular injection of hydroxyzine (1 mg.kg‐1)
Number of subjects: 45
Study 7739102 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam-famotidine suppository
Number of subjects: 45
Study 1784664 — intervention group
Group type: EXPERIMENTAL
Intervention: ALCOHOL label
Number of subjects: 60
Study 1784664 — intervention group
Group type: COMPARATOR
Intervention: WATER label
Number of subjects: 60
Study 1784664 — intervention group
Group type: COMPARATOR
Intervention: NOT ALCOHOL label
Number of subjects: 60
Study 6908098 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency contracting
Number of subjects: 115
Study 6908098 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education
Number of subjects: 115
Study 6908098 — intervention group
Group type: COMPARATOR
Intervention: Routine clinic care
Number of subjects: 115
Study 31838445 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine e‐cigarette (8 mg/mL nicotine concentration)
Number of subjects: 210
Study 31838445 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine‐free e‐cigarettes (placebo)
Number of subjects: 210
Study 31838445 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 210
Study 29532718 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with cisplatin fluorouracil followed by conventional radiotherapy
Number of subjects: 71
Study 29532718 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy with concurrent cisplatin
Number of subjects: 71
Study 28599833 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 40
Study 28599833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40